270 related articles for article (PubMed ID: 33574092)
1. The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
[TBL] [Abstract][Full Text] [Related]
2. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
3. MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway.
Wu G; Liu A; Zhu J; Lei F; Wu S; Zhang X; Ye L; Cao L; He S
Oncotarget; 2015 Oct; 6(30):28882-94. PubMed ID: 26337084
[TBL] [Abstract][Full Text] [Related]
4. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling.
Han P; Li JW; Zhang BM; Lv JC; Li YM; Gu XY; Yu ZW; Jia YH; Bai XF; Li L; Liu YL; Cui BB
Mol Cancer; 2017 Jan; 16(1):9. PubMed ID: 28086904
[TBL] [Abstract][Full Text] [Related]
5. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
[TBL] [Abstract][Full Text] [Related]
6. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q
Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071
[TBL] [Abstract][Full Text] [Related]
7. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
Shi L; Xi J; Xu X; Peng B; Zhang B
Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
[TBL] [Abstract][Full Text] [Related]
8. HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling.
Jiang N; Zou C; Zhu Y; Luo Y; Chen L; Lei Y; Tang K; Sun Y; Zhang W; Li S; He Q; Zhou J; Chen Y; Luo J; Jiang W; Ke Z
Theranostics; 2020; 10(6):2553-2570. PubMed ID: 32194819
[No Abstract] [Full Text] [Related]
9. Long non-coding RNA CCAT1 is a prognostic biomarker for the progression of oral squamous cell carcinoma via miR-181a-mediated Wnt/β-catenin signaling pathway.
Li GH; Ma ZH; Wang X
Cell Cycle; 2019 Nov; 18(21):2902-2913. PubMed ID: 31599709
[TBL] [Abstract][Full Text] [Related]
10. MiR-30-5p suppresses cell chemoresistance and stemness in colorectal cancer through USP22/Wnt/β-catenin signaling axis.
Jiang S; Miao D; Wang M; Lv J; Wang Y; Tong J
J Cell Mol Med; 2019 Jan; 23(1):630-640. PubMed ID: 30338942
[TBL] [Abstract][Full Text] [Related]
11. miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2.
Chen HY; Lang YD; Lin HN; Liu YR; Liao CC; Nana AW; Yen Y; Chen RH
Sci Rep; 2019 Jul; 9(1):9687. PubMed ID: 31273221
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-130b targets PTEN to induce resistance to cisplatin in lung cancer cells by activating Wnt/β-catenin pathway.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Cell Biochem Funct; 2018 Jun; 36(4):194-202. PubMed ID: 29653464
[TBL] [Abstract][Full Text] [Related]
13. HBX-induced miR-5188 impairs FOXO1 to stimulate β-catenin nuclear translocation and promotes tumor stemness in hepatocellular carcinoma.
Lin X; Zuo S; Luo R; Li Y; Yu G; Zou Y; Zhou Y; Liu Z; Liu Y; Hu Y; Xie Y; Fang W; Liu Z
Theranostics; 2019; 9(25):7583-7598. PubMed ID: 31695788
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
16. Rotavirus-Mediated Suppression of miRNA-192 Family and miRNA-181a Activates Wnt/β-Catenin Signaling Pathway: An In Vitro Study.
Banerjee A; Chawla-Sarkar M; Mukherjee A
Viruses; 2022 Mar; 14(3):. PubMed ID: 35336965
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition.
Warrier S; Bhuvanalakshmi G; Arfuso F; Rajan G; Millward M; Dharmarajan A
Cancer Gene Ther; 2014 Sep; 21(9):381-8. PubMed ID: 25104726
[TBL] [Abstract][Full Text] [Related]
18. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
19. Netrin-like domain of sFRP4, a Wnt antagonist inhibits stemness, metastatic and invasive properties by specifically blocking MMP-2 in cancer stem cells from human glioma cell line U87MG.
Yasmin IA; Mohana Sundaram S; Banerjee A; Varier L; Dharmarajan A; Warrier S
Exp Cell Res; 2021 Dec; 409(2):112912. PubMed ID: 34762897
[TBL] [Abstract][Full Text] [Related]
20. The STAT3-miRNA-92-Wnt Signaling Pathway Regulates Spheroid Formation and Malignant Progression in Ovarian Cancer.
Chen MW; Yang ST; Chien MH; Hua KT; Wu CJ; Hsiao SM; Lin H; Hsiao M; Su JL; Wei LH
Cancer Res; 2017 Apr; 77(8):1955-1967. PubMed ID: 28209618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
